Table 2 Reduction in pain scores by 50%, 25% and reduction in pain score by at least two points from baseline (T0) pain score
Lignocaine (n = 31) Yes/No (%)Saline (n = 32) Yes/No (%)Relative Risk (95% CI)p-value
Reduction by 50% in pain score from T0 (Yes/ No)
    Measured by patient
        T1016/15 (52) *8/24 (25)2.06 (1.03–4.11)0.03
        T2021/10 (68)16/16 (50)1.35 (0.88–2.06)0.15
        T3028/3 (90)20/12 (63)1.44 (1.07–1.93)0.009
    Measured by doctor
        T3026/5 (84)21/11 (66)1.27 (0.95–1.71)0.09
Reduction by 25% in pain score from T0 (Yes/No)
    Measured by patient
        T1024/7 (77) *14/18 (44)1.76 (1.14–2.73)0.006
        T2025/6 (81)18/14 (56)1.43 (1.01–2.03)0.03
        T3028/3 (90)22/10 (69)1.31 (1.01–1.70)0.03
    Measured by doctor
        T3028/3 (90)25/7 (78)1.15 (0.93–1.43)0.18
Two-point pain score reduction from T0 (Yes/No)
    Measured by patient
        T1023/8* (74)15/17 (47)1.58 (1.03–2.41)0.026
        T2025/6 (81)19/13 (59)1.35 (0.97–1.89)0.06
        T3028/3 (90)23/9 (72)1.25 (0.98–1.60)0.06
    Measured by doctor
        T3027/4 (87)22/10 (69)1.26 (0.96–1.65)0.07

  • *One lignocaine patient was missing a T10 pain score and was thus assumed to have been a failure at T10.